NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 15,866 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $22.01, for a total transaction of $349,210.66. Following the completion of the transaction, the chief executive officer now owns 774,040 shares in the company, valued at approximately $17,036,620.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Asaf Danziger also recently made the following trade(s):

  • On Monday, September 25th, Asaf Danziger sold 900 shares of NovoCure Limited stock. The shares were sold at an average price of $22.05, for a total transaction of $19,845.00.
  • On Wednesday, September 13th, Asaf Danziger sold 35,500 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $781,355.00.
  • On Thursday, September 14th, Asaf Danziger sold 37,272 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $820,356.72.

NovoCure Limited (NASDAQ NVCR) traded up $0.30 during trading on Friday, reaching $21.80. 704,863 shares of the company’s stock were exchanged, compared to its average volume of 1,044,118.

NovoCure Limited (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. The firm had revenue of $50.10 million during the quarter, compared to the consensus estimate of $43.45 million. NovoCure Limited had a negative net margin of 47.45% and a negative return on equity of 57.68%. The firm’s revenue was up 130.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.39) earnings per share. research analysts predict that NovoCure Limited will post -0.63 earnings per share for the current fiscal year.

WARNING: “NovoCure Limited (NVCR) CEO Asaf Danziger Sells 15,866 Shares of Stock” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/novocure-limited-nvcr-ceo-asaf-danziger-sells-15866-shares-of-stock/1676539.html.

Several brokerages have issued reports on NVCR. Deutsche Bank AG reaffirmed a “hold” rating and issued a $19.00 price objective (up previously from $18.00) on shares of NovoCure Limited in a research report on Monday, July 17th. BidaskClub raised shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of NovoCure Limited from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Mizuho began coverage on shares of NovoCure Limited in a research report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective (down previously from $29.00) on shares of NovoCure Limited in a research report on Friday, October 27th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $21.00.

A number of institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc lifted its stake in NovoCure Limited by 8.5% in the second quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 1,092 shares during the last quarter. American International Group Inc. lifted its stake in NovoCure Limited by 7.1% in the first quarter. American International Group Inc. now owns 31,191 shares of the medical equipment provider’s stock valued at $253,000 after buying an additional 2,065 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in NovoCure Limited by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock valued at $1,406,000 after buying an additional 2,480 shares during the last quarter. California State Teachers Retirement System lifted its stake in NovoCure Limited by 2.6% in the second quarter. California State Teachers Retirement System now owns 102,309 shares of the medical equipment provider’s stock valued at $1,770,000 after buying an additional 2,600 shares during the last quarter. Finally, Teachers Advisors LLC lifted its stake in NovoCure Limited by 3.3% in the first quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock valued at $800,000 after buying an additional 3,125 shares during the last quarter. 36.20% of the stock is owned by hedge funds and other institutional investors.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.